# Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction

Study · id `cardio:ct-nct01781390` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01781390](<https://clinicaltrials.gov/study/NCT01781390>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01781390

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT01781390. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-11 (actual); primary completion 2021-04-06 (actual). Results posted on 2022-01-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT01781390, source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)
- Started: 2013-03-11 (actual) (ClinicalTrials.gov record NCT01781390, source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)
- Primary completion: 2021-04-06 (actual) (ClinicalTrials.gov record NCT01781390, source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)
- Completion: 2021-04-06 (actual) (ClinicalTrials.gov record NCT01781390, source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)
- Results first posted: 2022-01-18 (ClinicalTrials.gov record NCT01781390, source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01781390-2022-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
- Acronym: AMICI
- Condition: Acute Myocardial Infarction
- Intervention (Other): Placebo
- Intervention (Biological): Mesenchymal Precursor Cells (MPC) 12.5 M
- Intervention (Biological): Mesenchymal Precursor Cells (MPC) 25 M
- Lead sponsor: Mesoblast, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: 4291d977b65406969a5501204e251775db800eff91858b53ef8a25e684c9eecb
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
